Chronic cerebral ischemia (CCI) is a common cerebrovascular syndrome, the development of which is associated with a high risk of increasing cognitive, behavioral, and motor disorders, and the formation of a patient's dependence on others. Timely start of treatment can slow down the course of the disease, make it more favorable. The review considers the possibility of using the domestic neuroprotector mexidol in patients with CCI. The results of a series of clinical studies on the use of ethylmethylhydroxypyridine succinate (mexidol) in patients with CCI are analyzed. The effectiveness of the drug in relieving cognitive, affective and motor disorders is noted. Information about the good tolerance of mexidol is presented.

Download full-text PDF

Source
http://dx.doi.org/10.17116/jnevro2020120061119DOI Listing

Publication Analysis

Top Keywords

ethylmethylhydroxypyridine succinate
8
chronic cerebral
8
motor disorders
8
mexidol patients
8
patients cci
8
[efficacy safety
4
safety ethylmethylhydroxypyridine
4
succinate patients
4
patients chronic
4
cerebral ischemia]
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!